AGIOS PHARMACEUTICALS ($AGIO) posted quarterly earnings results on Thursday, October 30th. The company reported earnings of -$1.78 per share, beating estimates of -$1.94 by $0.16. The company also reported revenue of $12,880,000, beating estimates of $10,625,340 by $2,254,660.
You can see Quiver Quantitative's $AGIO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AGIOS PHARMACEUTICALS Insider Trading Activity
AGIOS PHARMACEUTICALS insiders have traded $AGIO stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $AGIO stock by insiders over the last 6 months:
- BRIAN GOFF (Chief Executive Officer) has made 0 purchases and 3 sales selling 29,785 shares for an estimated $1,033,684.
- SARAH GHEUENS (Chief Medical Officer) has made 0 purchases and 5 sales selling 22,216 shares for an estimated $834,982.
- THEODORE JAMES JR. WASHBURN (Principal Accounting Officer) sold 8,546 shares for an estimated $315,091
- CECILIA JONES (Chief Financial Officer) has made 0 purchases and 2 sales selling 5,431 shares for an estimated $193,948.
- JAMES WILLIAM BURNS (Chief Legal Officer) sold 2,799 shares for an estimated $93,878
- TSVETA MILANOVA (Chief Commercial Officer) sold 2,770 shares for an estimated $92,905
- DAVID SCADDEN has made 0 purchases and 3 sales selling 1,800 shares for an estimated $72,200.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AGIOS PHARMACEUTICALS Hedge Fund Activity
We have seen 104 institutional investors add shares of AGIOS PHARMACEUTICALS stock to their portfolio, and 101 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP added 1,142,511 shares (+inf%) to their portfolio in Q2 2025, for an estimated $37,999,915
- POLAR CAPITAL HOLDINGS PLC removed 1,002,036 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $33,327,717
- ARMISTICE CAPITAL, LLC removed 880,000 shares (-43.0%) from their portfolio in Q2 2025, for an estimated $29,268,800
- TCG CROSSOVER MANAGEMENT, LLC added 697,003 shares (+inf%) to their portfolio in Q2 2025, for an estimated $23,182,319
- ROCK SPRINGS CAPITAL MANAGEMENT LP added 647,565 shares (+189.2%) to their portfolio in Q2 2025, for an estimated $21,538,011
- STATE STREET CORP removed 498,366 shares (-20.3%) from their portfolio in Q2 2025, for an estimated $16,575,653
- WELLINGTON MANAGEMENT GROUP LLP added 397,667 shares (+1625.7%) to their portfolio in Q2 2025, for an estimated $13,226,404
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AGIOS PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $AGIO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Scotiabank issued a "Sector Outperform" rating on 07/28/2025
- B of A Securities issued a "Buy" rating on 07/22/2025
To track analyst ratings and price targets for AGIOS PHARMACEUTICALS, check out Quiver Quantitative's $AGIO forecast page.
AGIOS PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $AGIO recently. We have seen 3 analysts offer price targets for $AGIO in the last 6 months, with a median target of $56.0.
Here are some recent targets:
- Emily Bodnar from HC Wainwright & Co. set a target price of $56.0 on 09/04/2025
- Greg Harrison from Scotiabank set a target price of $65.0 on 07/28/2025
- Greg Harrison from B of A Securities set a target price of $51.0 on 07/22/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
